Walden 6630 Psychopharmacology Midterm Study Guide
1. Mood, emotion, feeding, and reproductive behavior: Serotonin regulates
2. SSRIs: This class of antidepressants binds to presynaptic SERT and inhibits
them from reuptake of serotonin to increase levels in the synaptic cleft to bind with
postsysnaptic 5HT2 receptors
3. SSRIs: First line therapy for MDD due to milder side effect profiles
4. citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine: Six
Common SSRIs
5. 4-6 weeks: Onset of therapeutic benefit from SSRIs
6. Chronic Anxiety, PTSD, OCD, and eating disorders (bulimia): In addition to
MDD, SSRIs also treat
7. Anxiety, insomnia, GI distress, sexual dysfunction (ED), SIADH: Five Com-
mon side effects of SSRIs include
8. suicidal ideation: Severe side effect of SSRIs in children/adolescents under age
25 years old
9. Serotonin Syndrome: Life threatening adverse effect of SSRIs, especially when
used in combination with other serotonergic drugs (SNRIs, TCAs, MAOIs, etc.)
10. Serotonin Syndrome: Excess accumulation of serotonin resulting in overstim-
ulation of the nervous system
11. Flushing, hyperthermia, agitation, muscle rigidity, seizure, coma, HYPER-
reflexia: Seven symptoms of Serotonin Syndrome
12. Cyproheptadine (5-HT2 receptor antagonist): The treatment for serotonin
syndrome
13. blocking 5-HT2 receptors (serotonin antagonist): Cyproheptadine treats
serotonin syndrome by
14. Irritability, headaches, and insomnia: When SSRIs or SNRIs are stopped
abruptly, common symptoms of withdrawal include
15. Prolonged QT interval (normal=0.4.-0.44 seconds): Medicine specific side
effect of citalopram
16. Paroxetine: This SSRI is pregnancy category D due to associations with con-
genital heart defects
17. C: All SSRIs but paroxetine (D) are pregnancy category
18. fluoxetine, fluvoxamine, and paroxetine: Three SSRIs that are inhibitors of
Cytochrome P450 enzymes
19. duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran: -
Five common SNRIs include
20. SNRIs: This antidepressant class of medications works by binding to presynap-
tic SERT and NET to inhibit them from reuptake of serotonin and norepinephrine to
increase their levels in the synaptic cleft
, Walden 6630 Psychopharmacology Midterm Study Guide
21. Anxiety and neuropathic pain (peripheral neuropathy): In addition to MDD
SNRIs treat
22. urinary incontinence and Fibromyalgia: Medication specific indications of
duloxetine:
23. social anxiety, panic disorders, PTSD, OCD, postmenopausal hot flashes-
: Medication specific indications of venlafaxine:
24. Insomnia, nausea, sexual dysfunction, hypertension, sweating,
headaches: Six common side effects of SNRIs include:
25. suicidal ideation: Severe side effect of SNRIs in children/adolescents under
age 25 years old:
26. Serotonin Syndrome: Life threatening adverse effect of SNRIs, especially
when used in combination with other serotonergic drugs:
27. venlafaxine: This SNRI is an inhibitor of Cytochrome P450 enzymes:
28. duloxetine: This SNRI is hepatotoxic:
29. Serotonin, Norepinephrine, and Dopamine: MAOIs increase the levels of:
30. alertness and focus: Norepinephrine regulates:
31. cognitive function, motivation, and awakeness: Dopamine regulates:
32. Serotonin, Norepinephrine, and Dopamine: In the synaptic cleft, Monoamine
Oxidase A breaks down:
33. Dopamine: In the synaptic cleft, Monoamine Oxidase B breaks down:
34. Atypical depression (mood responds to positive events and symptoms
include increased appetite, weight gain, sleepiness, and fatigue): MAOIs are
especially effective in:
35. MAO-A and MAO-B: Non-selective MAOIs inhibit enzymes:
36. MAO-B: Selective MAOIs only inhibit the enzyme:
37. isocarboxazid, phenelzine, tranylcypromine: Three non-selective MAOIs:
38. Serotonin, Norepinephrine, Dopamine: Non-selective MAOIs increase the lev-
els of these neurotransmitters:
39. isocarboxazid, phenelzine, tranylcypromine: These three non-selective
MAOIs bind irreversibly to MAO enzymes to permanently block their function:
40. selegeline, rasagiline: Two selective MAOIs:
41. Dopamine: Selective MAOIs increase the level of this neurotransmitter:
42. selegeline, rasagiline: These selective MAOIs are more commonly prescribed
to treat Parkinson's Disease (a neurodegenerative disorder that effects the dopamin-
ergic neurons in the substantia nigra region of the brain):
43. Serotonin syndrome and hypertensive crisis: Adverse effects of MAOIs in-
clude:
1. Mood, emotion, feeding, and reproductive behavior: Serotonin regulates
2. SSRIs: This class of antidepressants binds to presynaptic SERT and inhibits
them from reuptake of serotonin to increase levels in the synaptic cleft to bind with
postsysnaptic 5HT2 receptors
3. SSRIs: First line therapy for MDD due to milder side effect profiles
4. citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine: Six
Common SSRIs
5. 4-6 weeks: Onset of therapeutic benefit from SSRIs
6. Chronic Anxiety, PTSD, OCD, and eating disorders (bulimia): In addition to
MDD, SSRIs also treat
7. Anxiety, insomnia, GI distress, sexual dysfunction (ED), SIADH: Five Com-
mon side effects of SSRIs include
8. suicidal ideation: Severe side effect of SSRIs in children/adolescents under age
25 years old
9. Serotonin Syndrome: Life threatening adverse effect of SSRIs, especially when
used in combination with other serotonergic drugs (SNRIs, TCAs, MAOIs, etc.)
10. Serotonin Syndrome: Excess accumulation of serotonin resulting in overstim-
ulation of the nervous system
11. Flushing, hyperthermia, agitation, muscle rigidity, seizure, coma, HYPER-
reflexia: Seven symptoms of Serotonin Syndrome
12. Cyproheptadine (5-HT2 receptor antagonist): The treatment for serotonin
syndrome
13. blocking 5-HT2 receptors (serotonin antagonist): Cyproheptadine treats
serotonin syndrome by
14. Irritability, headaches, and insomnia: When SSRIs or SNRIs are stopped
abruptly, common symptoms of withdrawal include
15. Prolonged QT interval (normal=0.4.-0.44 seconds): Medicine specific side
effect of citalopram
16. Paroxetine: This SSRI is pregnancy category D due to associations with con-
genital heart defects
17. C: All SSRIs but paroxetine (D) are pregnancy category
18. fluoxetine, fluvoxamine, and paroxetine: Three SSRIs that are inhibitors of
Cytochrome P450 enzymes
19. duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran: -
Five common SNRIs include
20. SNRIs: This antidepressant class of medications works by binding to presynap-
tic SERT and NET to inhibit them from reuptake of serotonin and norepinephrine to
increase their levels in the synaptic cleft
, Walden 6630 Psychopharmacology Midterm Study Guide
21. Anxiety and neuropathic pain (peripheral neuropathy): In addition to MDD
SNRIs treat
22. urinary incontinence and Fibromyalgia: Medication specific indications of
duloxetine:
23. social anxiety, panic disorders, PTSD, OCD, postmenopausal hot flashes-
: Medication specific indications of venlafaxine:
24. Insomnia, nausea, sexual dysfunction, hypertension, sweating,
headaches: Six common side effects of SNRIs include:
25. suicidal ideation: Severe side effect of SNRIs in children/adolescents under
age 25 years old:
26. Serotonin Syndrome: Life threatening adverse effect of SNRIs, especially
when used in combination with other serotonergic drugs:
27. venlafaxine: This SNRI is an inhibitor of Cytochrome P450 enzymes:
28. duloxetine: This SNRI is hepatotoxic:
29. Serotonin, Norepinephrine, and Dopamine: MAOIs increase the levels of:
30. alertness and focus: Norepinephrine regulates:
31. cognitive function, motivation, and awakeness: Dopamine regulates:
32. Serotonin, Norepinephrine, and Dopamine: In the synaptic cleft, Monoamine
Oxidase A breaks down:
33. Dopamine: In the synaptic cleft, Monoamine Oxidase B breaks down:
34. Atypical depression (mood responds to positive events and symptoms
include increased appetite, weight gain, sleepiness, and fatigue): MAOIs are
especially effective in:
35. MAO-A and MAO-B: Non-selective MAOIs inhibit enzymes:
36. MAO-B: Selective MAOIs only inhibit the enzyme:
37. isocarboxazid, phenelzine, tranylcypromine: Three non-selective MAOIs:
38. Serotonin, Norepinephrine, Dopamine: Non-selective MAOIs increase the lev-
els of these neurotransmitters:
39. isocarboxazid, phenelzine, tranylcypromine: These three non-selective
MAOIs bind irreversibly to MAO enzymes to permanently block their function:
40. selegeline, rasagiline: Two selective MAOIs:
41. Dopamine: Selective MAOIs increase the level of this neurotransmitter:
42. selegeline, rasagiline: These selective MAOIs are more commonly prescribed
to treat Parkinson's Disease (a neurodegenerative disorder that effects the dopamin-
ergic neurons in the substantia nigra region of the brain):
43. Serotonin syndrome and hypertensive crisis: Adverse effects of MAOIs in-
clude:
